Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's Disease

Inclusion Criteria: * Fluent in English * Diagnosis of mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease via previously documented clinical assessment * Amyloid positive by PET or cerebrospinal fluid criteria * Stable medical condition for 3 months prior to screening visit * Stable medications for general medical conditions for 4 weeks prior to the screening and study visits (exceptions may be made on a case-by-case basis by study clinician) * Stable on Anti-Amyloid Targeting Therapy (lecanemab or donanemab) for at least 8 weeks prior to Baseline Visit * If receiving an acetylcholinesterase inhibitor (donepezil, rivastigmine, galantamine) or memantine or both, must be stable on a dose for at least 30 days prior to Baseline Visit * Clinical laboratory values must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the study clinician * Participants must have a study partner who agrees to participate throughout the duration of the study. The study partner must have frequent and sufficient contact (approximately 10 hours per week) with the participant and be able to provide accurate information regarding the participant's cognitive and functional abilities. Exclusion Criteria: * A diagnosis of dementia other than Alzheimer's disease * History of a clinically significant stroke, history of transient ischemic attack within 12 months, or any history of seizures * Current evidence or history in past two years of…